Egalet Lines Up Cash In Deal With Japan’s Shionogi Ahead Of IPO
This article was originally published in PharmAsia News
The specialty pharma will receive $10 million upfront from Shionogi in exchange for rights to multiple oral abuse-deterrent hydrocodone opioid products. The Japanese pharma also agreed to buy $15 million in stock to close with Egalet’s IPO.
You may also be interested in...
European Notebook: U.S. Investors Tap Into Europe; New U.K. Pricing Scheme; Pfizer Dismayed By German Payers
Europe's IPO window remains closed but the region still attracts U.S. investors; drug spending set to decline in Greece and Spain in 2014; Pfizer takes Bosulif off the German market because agreement on price unlikely with health insurers; no room for value-based pricing in the U.K.; European Parliament clears €80 billion in research funding under Horizon 2020.
There will be no generics of original OxyContin; FDA says it can no longer serve as a reference product because it has a greater abuse potential than the reformulation, where Purdue has secured particularly strong language regarding reducing intranasal abuse.
Endo says label differentiation in the guidance is a positive step; Commissioner Hamburg tells Congress that if new opioid formulations “significantly” deter abuse, generic versions will have to as well.